Form 4: Regeneron Executive George Yancopoulos Reports Stock Sale

George Yancopoulos, a Director, Bd. Co-Chair, President & CSO of Regeneron Pharmaceuticals, Inc., reported the sale of 16,848 shares of common stock at $900 per share on January 2, 2024, according to a Form 4 filing.

Summary

• On January 2, 2024, George Yancopoulos, a Director, Bd. Co-Chair, President & CSO of Regeneron Pharmaceuticals, Inc., sold 16,848 shares of common stock at a price of $900 per share.
• Following the transaction, Yancopoulos directly owns 752,486 shares of Regeneron common stock.
• Yancopoulos also indirectly owns shares through a trust for his children (180,000 shares), a 401(k) plan (5,889 shares), and two GRATs (121,071 and 158,410 shares respectively).

Sentiment

Score: 5

Explanation: The sentiment is neutral. The stock sale is disclosed and executed under a pre-arranged plan, suggesting it's not necessarily indicative of a negative outlook, but the market may react cautiously.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's prospects. A sale of this size by a high-ranking executive may be viewed with caution, although the pre-arranged trading plan mitigates some concerns.

Comparison to Industry Standards

• It's common for executives at publicly traded companies, such as Regeneron, Amgen, and Gilead, to utilize 10b5-1 trading plans to manage their stock sales and avoid accusations of insider trading.
• The volume of shares sold is within the typical range for executive transactions, but the market will likely compare this sale to similar transactions by executives at peer companies to gauge sentiment.

Stakeholder Impact

• Shareholders may react to the news of the stock sale, although the pre-arranged trading plan may mitigate concerns.
• The transaction does not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates